en
Scientific article
English

Desmoteplase 3 to 9 Hours After Major Artery Occlusion Stroke: The DIAS-4 Trial (Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke)

Published inStroke, vol. 47, no. 12, p. 2880-2887
Publication date2016
Abstract

The DIAS-3 trial (Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke [phase 3]) did not demonstrate a significant clinical benefit of desmoteplase administered 3 to 9 hours after stroke in patients with major artery occlusion. We present the results of the prematurely terminated DIAS-4 trial together with a post hoc pooled analysis of the concomitant DIAS-3, DIAS-4, and DIAS-J (Japan) trials to better understand the potential risks and benefits of intravenous desmoteplase for the treatment of ischemic stroke in an extended time window.

Keywords
  • Aged
  • Aged
  • 80 and over
  • Arterial Occlusive Diseases/complications
  • Brain Ischemia/drug therapy/etiology
  • Cerebral Arterial Diseases/complications
  • Early Termination of Clinical Trials
  • Female
  • Fibrinolytic Agents/administration & dosage/adverse effects/pharmacology
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Outcome Assessment (Health Care)
  • Plasminogen Activators/administration & dosage/adverse effects/pharmacology
  • Stroke/drug therapy/etiology
Citation (ISO format)
VON KUMMER, Rüdiger et al. Desmoteplase 3 to 9 Hours After Major Artery Occlusion Stroke: The DIAS-4 Trial (Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke). In: Stroke, 2016, vol. 47, n° 12, p. 2880–2887. doi: 10.1161/STROKEAHA.116.013715
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal0039-2499
342views
0downloads

Technical informations

Creation08/30/2017 2:33:00 PM
First validation08/30/2017 2:33:00 PM
Update time03/15/2023 2:25:27 AM
Status update03/15/2023 2:25:26 AM
Last indexation01/17/2024 1:29:19 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack